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Following the well-known epidemiological study 
conducted in Northwest Greenland in the 1970s 
(Dyerberg et al., 1978), several clinical assess-
ments have indicated that a diet rich in 3 poly-
unsaturated fatty acids (PUFAs) has beneficial 
effects in various inflammatory diseases, including 
asthma, psoriasis, inflammatory bowel diseases, 
and rheumatoid arthritis (Horrobin, 1987). Al-
though it remains unclear how 3 PUFAs exert 
such antiinflammatory effects, recent studies have 
identified several derivatives of 3 PUFAs that 
possess strong antiinflammatory effects (Serhan 
et al., 2008; Tull et al., 2009). Resolvin E1 (RvE1) 
is one such antiinflammatory lipid mediator.
RvE1 is known to exert its actions through 
two receptors, BLT1 and ChemR23 (Arita et al., 
2007). RvE1 binds to BLT1, a G protein–coupled 
receptor for leukotriene B4 (LTB4), and inhibits 
BLT1 signals (Arita et al., 2007). In addition, RvE1 
exhibits an agonistic activity toward ChemR23 
(Arita et al., 2007), a G protein–coupled recep-
tor for chemerin. The antiinflammatory effects 
of RvE1 have been demonstrated in acute in-
nate immune inflammation, such as peritonitis 
(Arita et al., 2007) and colitis (Arita et al., 2005b). 
In these models, RvE1 exerted its antiinflamma-
tory effects by inhibiting neutrophil infiltration 
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Resolvin E1 (RvE1) is a lipid mediator derived from 3 polyunsaturated fatty acids that 
exerts potent antiinflammatory roles in several murine models. The antiinflammatory 
mechanism of RvE1 in acquired immune responses has been attributed to attenuation of 
cytokine production by dendritic cells (DCs). In this study, we newly investigated the effect 
of RvE1 on DC motility using two-photon microscopy in a contact hypersensitivity (CHS) 
model and found that RvE1 impaired DC motility in the skin. In addition, RvE1 attenuated  
T cell priming in the draining lymph nodes and effector T cell activation in the skin, which 
led to the reduced skin inflammation in CHS. In contrast, leukotriene B4 (LTB4) induced 
actin filament reorganization in DCs and increased DC motility by activating Cdc42 and 
Rac1 via BLT1, which was abrogated by RvE1. Collectively, our results suggest that RvE1 
attenuates cutaneous acquired immune responses by inhibiting cutaneous DC motility, 
possibly through LTB4-BLT1 signaling blockade.
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2008). However, the effect of RvE1 on DC motility has not 
been investigated in the context of acquired immunity.
In the peripheral tissues such as the skin, DCs migrate in 
an amoeboid movement that requires actin polymerization 
via activation of the Rho family of small GTPases, such as 
Cdc42, Rac, and Rho A (Lämmermann and Germain, 2014). 
In acquired immunity such as contact hypersensitivity (CHS), 
upon uptake of foreign antigens, DCs migrate to the draining 
LNs (dLNs) via lymphatic vessels to establish sensitization by 
inducing the antigen-specific T cell differentiation (Honda et al., 
2013). In elicitation, DC migration to form DC–T cell cluster-
ing is required for efficient antigen presentation in situ (Natsuaki 
et al., 2014). Thus, active DC motility is an essential factor 
for acquired immunity.
In this study, we investigated the effects and underlying 
mechanisms of RvE1 on DC motility using a CHS model, 
which is a prototype of delayed-type hypersensitivity in the 
skin mediated by IFN- (Mori et al., 2008; Honda et al., 
2013). RvE1 inhibited cutaneous DC migration into the 
dLNs and suppressed antigen-specific T cell induction in the 
sensitization phase. In addition, live imaging analysis revealed 
that RvE1 inhibited cutaneous DC motility and cluster for-
mation in the skin, which subsequently attenuated activation 
of effector T cells in the skin in the elicitation phase of CHS. 
Intriguingly, LTB4 induced actin filament reorganization in 
DCs and increased DC motility by activating Cdc42 and 
Rac1 via BLT1, which was abrogated by RvE1. These results 
suggest that RvE1 exerts its antiinflammatory effects in cuta-
neous acquired immunity by inhibiting DC motility, possibly 
through an LTB4-BLT1 signaling blockade.
RESULTS
RvE1 inhibits DC migration from skin to dLNs
To examine the effect of RvE1 on cutaneous DC migration to 
dLNs, we used an FITC-induced cutaneous DC migration 
assay in the presence or absence of RvE1. Mice treated with 
RvE1 exhibited a significantly reduced number of migrated 
DCs in the dLNs, suggesting that RvE1 regulates cutaneous 
DC migration (Fig. 1, A and B). We next sought to identify the 
receptors through which RvE1 exerts the inhibitory effects on 
cutaneous DC migration. RvE1 is known to elicit its functions 
via two receptors, BLT1 and ChemR23 (Arita et al., 2007). 
We first examined the involvement of ChemR23 signaling 
on cutaneous DC migration using chemerin, a ChemR23 ag-
onist, with two different doses (500 ng/body and 5 µg/body) 
according to previous studies (Luangsay et al., 2009; Lin et al., 
2014). However, the ChemR23 agonist did not affect cutane-
ous DC migration in these conditions (not depicted).
Then, we examined the involvement of BLT1 in the ef-
fects of RvE1 using BLT1-deficient mice. BLT1-deficient 
mice exhibited impaired cutaneous DC migration, which was 
similar to the extent of RvE1-treated WT mice (Fig. 1 C). No 
additional inhibitory effect of RvE1 on DC migration was 
observed in BLT1-deficient mice (Fig. 1 C), suggesting the 
involvement of BLT1 in the inhibitory effect of RvE1.
into the inflammatory foci through a blockade of LTB4-BLT1 
signaling in neutrophils (Haas-Stapleton et al., 2007). In con-
trast, few studies have been conducted on the effect of RvE1 
on acquired immune responses, in which DCs and T cells play 
major roles in the development. In these studies, the attenu-
ated cytokine production, such as IL-12 and IL-23, from DCs 
is considered as the major mechanism by which RvE1 exerts 
the antiinflammatory effects (Arita et al., 2005a; Haworth et al., 
Figure 1. Inhibition of DC migration in the inflammatory state 
by RvE1 or a BLT1 antagonist. (A–C) FITC-induced DC migration assay. 
(A) Representative FACS plots of FITC+ MHC class II+ cells in dLNs. Mice 
were treated with either vehicle or RvE1 (200 ng/mouse) 30 min before 
and 1 d after FITC application. LN cell suspensions were prepared from 
dLNs 48 h after FITC application and subjected to a flow cytometric analy-
sis. (B) Number of migrated FITC+ MHC class II+ DCs in dLNs (n = 4).  
(C) Number of migrated DCs in WT and BLT1-deficient mice (n = 3).  
(D) Number of migrated FITC-positive Langerhans cells (EpCAM+), CD103+ 
dermal DCs, and CD103 dermal DCs in WT and BLT1-deficient mice  
(n = 3). (E) LTB4 production by BMDCs after TNF stimulation. BMDCs were 
stimulated with 100 ng/ml TNF for 12 h, and the LTB4 concentration in 
culture supernatant was measured by ELISA. (F) Transwell migration assay. 
WT or BLT1-deficient BMDCs pretreated with 100 nM RvE1, 10 nM BLT1 
antagonist, or 100 µM ChemR23 agonist were incubated with or without 
100 ng/ml TNF and examined for chemotaxis to 100 ng/ml CCL21. The 
migrated BMDC number was evaluated by flow cytometry. Data are pre-
sented as the percentage of migrated DCs to total input. Results are ex-
pressed as the mean ± SEM. All p-values were obtained by Student’s t test: 
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the cells without tissue damage and inflammation (Tomura 
et al., 2010).
The abdominal skin of Kaede transgenic mice was ex-
posed to innocuous violet light (Fig. 3 A) for labeling skin 
cells as red by photoconversion. The number of migrated 
cutaneous DCs (Kaede-red DCs) from the skin to dLNs was 
significantly reduced in RvE1- or BLT1 antagonist–treated 
mice than that in vehicle-treated mice (Fig. 3, B and C). The 
motility of the three skin DC subsets was similarly affected by 
RvE1 or the BLT1 antagonist (Fig. 3 D). These results indi-
cate that LTB4-BLT1 signaling regulates cutaneous constitu-
tive DC migration to dLNs in the steady state skin as in the 
hapten-induced inflammatory skin.
LTB4-BLT1 signaling is essential for cutaneous DC motility
Next, we examined the in vivo mechanisms by which RvE1 
regulates cutaneous DC migration to dLNs. CD11c-YFP 
mice were used for the visualization of cutaneous DCs 
(Lindquist et al., 2004), and the ear skin of CD11c-YFP mice 
were subjected to two-photon microscopy observation for 
intravital imaging of cutaneous DCs (Honda et al., 2014; 
Natsuaki et al., 2014). 1 h after the initiation of the observation, 
mice were treated with vehicle, RvE1, or a BLT1 antagonist, 
and DC morphology and motility were observed for another 
3 h. Before RvE1 and/or BLT1 antagonist treatment, cutaneous 
DCs exhibited active motility with polarized morphology, 
filopodia- and lamellipodia-like structures at the leading edge, 
Because there are at least three DC subsets in the skin 
(Langerhans cells, CD103+ dermal DCs [Langerin-positive 
dermal DCs], and CD103 dermal DCs [Langerin-negative 
dermal DCs]; Honda et al., 2010), we examined the effect of 
RvE1 on each DC subset in an FITC-induced cutaneous DC 
migration assay. We found that RvE1 inhibited the migration 
of each DC subset similarly (Fig. 1 D). These results indicate 
that the effect of RvE1 may not be restricted to a particular 
DC subset.
To ascertain the aforementioned findings, we generated 
BMDCs and compared the effects of RvE1, BLT1 antagonist 
U-75302, and ChemR23 agonist chemerin on TNF-stimulated 
BMDC migration. First, we observed that BMDCs produced 
LTB4, which was significantly augmented by TNF stimula-
tion (Fig. 1 E). The TNF-induced chemotaxis toward CC 
chemokine ligand 21 (CCL21) was significantly impaired by 
RvE1 and BLT1 antagonist treatment, but not by ChemR23 
agonist treatment (Fig. 1 F). In addition, the attenuated che-
motaxis in BLT1-deficient BMDCs was not further impaired 
by RvE1 treatment (Fig. 1 F). These results suggest that RvE1 
regulates cutaneous DC migration through a blockade of au-
tonomous LTB4-BLT1 signaling pathway.
RvE1 suppresses the sensitization in CHS
Next, we evaluated the impact of impaired DC migration by 
RvE1 on acquired cutaneous immune response using a CHS 
model. We first examined the effect of RvE1 in the sensitiza-
tion phase of CHS because dermal DC migration to dLNs is 
an essential step for sensitization (Honda et al., 2013). WT 
mice treated with RvE1 exhibited a significantly reduced 
number of CD44+ CD62L+ central memory T cells and CD44+ 
CD62L effector memory T cells in dLNs after 0.5% 2,4-
dinitrofluorobenzene (DNFB) application (Fig. 2 A). In addition, 
antigen-specific T cell proliferation and IFN- production by 
dLN cells were significantly reduced in RvE1-treated WT 
mice (Fig. 2, B and C). Consistently, RvE1 significantly de-
creased the ear swelling response, an indicator of skin inflam-
mation, in WT mice (Fig. 2 D).
In contrast, BLT1-deficient mice exhibited a significantly 
reduced ear swelling response similar to that of RvE1-treated 
WT mice. RvE1 treatment did not impair the CHS response 
further in BLT1-deficient mice (Fig. 2 D), providing evi-
dence that RvE1 regulates cutaneous DC migration and sub-
sequent sensitization in CHS, possibly through a blockade of 
LTB4-BLT1 signaling.
RvE1 inhibits BLT1-induced cutaneous DC migration  
in the steady state
Cutaneous DCs constantly migrate to dLNs in both the in-
flammatory state (e.g., FITC-induced DC migration) and 
the noninflammatory steady state. To examine whether RvE1 
inhibits DC migration in the steady state, we applied a pho-
tolabeling system using Kaede transgenic mice. Kaede is a 
photoconvertible fluorescence protein that changes from green 
(Kaede-green) to red (Kaede-red) upon exposure to violet 
light (Ando et al., 2002). This system allows us to photolabel 
Figure 2. Decreased CHS response to DNFB by RvE1. (A) Flow cyto-
metric analysis for dLN cell composition 5 d after 0.5% DNFB application 
in the presence or absence of RvE1 treatment. Bars indicate the numbers 
in each cell subset (n = 4). (B) [3H]thymidine incorporation by dLN cells 
after DNBS stimulation. Cell suspensions of dLNs from DNFB-sensitized 
mice were cultured for 3 d with or without 50 or 100 µg/ml DNBS. Cells 
were pulsed with 0.5 µCi [3H]thymidine for the last 24 h and subjected to 
liquid scintillation counting. (C) ELISA analysis for measuring IFN- in the 
culture medium 48 h after the culture. (D) Ear thickness change at 24 and 
48 h after the challenge with 0.3% DNFB. WT and BLT1-deficient mice 
were treated with or without RvE1 (200 ng/mouse) 1 d and 30 min before 
sensitization (n = 4). Results are expressed as the mean ± SEM. All p-values 
were obtained by Student’s t test: *, P < 0.05. All data are representative 
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BLT1-deficient DCs (n = 4). The migration ratio (migrated 
DCs/skin-resident DCs) was significantly higher in WT DCs 
(0.0193 ± 0.0024 [mean ± SEM; n = 4]) than that in BLT1-
deficient DCs (0.0048 ± 0.0006 [mean ± SEM; n = 4]). 
These findings strongly support that LTB4-BLT1 signaling 
is intrinsically essential for cutaneous DC motility and that 
RvE1 inhibits DC motility in the skin, possibly by antago-
nizing the LTB4-BLT1 signaling in both the steady and the 
inflammatory states.
LTB4-BLT1 signaling mediates DC cluster formation  
in the skin
The aforementioned results suggest that BLT1-dependent 
DC motility plays a key role in CHS during both the sensi-
tization and elicitation phases because increased DC motility 
and subsequent DC cluster formation around the postcapil-
lary venules after the hapten application are essential for ef-
fector T cell activation in the skin during the elicitation 
phase (Natsuaki et al., 2014). In light of this, we next evalu-
ated the involvement of LTB4-BLT1 signaling in DC clus-
ter formation. The ear skin was subjected to whole-mount 
staining with anti–MHC class II antibody (Ab) 24 h after 
0.5% DNFB application, and the size and the number of 
DC clusters were evaluated. Although numerous large DC 
clusters were observed in vehicle-treated WT mice, both 
the number and the size of DC clusters were significantly 
reduced in RvE1- or BLT1 antagonist–treated WT mice 
and also vehicle-treated BLT1-deficient mice (Fig. 5, A and B). 
In addition, RvE1 treatment did not exhibit further inhibitory 
effects on DC cluster in BLT1-deficient mice (Fig. 5, A and B). 
and a trailing uropod-like structure (Video 1). However, 
30 min after RvE1 and/or BLT1 antagonist treatment, DCs 
became round in shape and their motility gradually decreased 
(Fig. 4 A and Videos 2–4). Consistently, individual DC tracking 
showed significantly decreased displacement, mean track ve-
locity, and straightness as a parameter of directionality in RvE1- 
and/or BLT1 antagonist–treated mice (Fig. 4, B and C). No 
additional inhibitory effect of RvE1 and BLT1 antagonist on 
DC motility was observed (Fig. 4, B and C). Furthermore, we 
confirmed that RvE1 treatment did not affect DC viability 
in vivo and in vitro (not depicted), excluding the possibility 
of a toxic effect of RvE1.
Next, we evaluated the DC motility under an inflamma-
tory condition. RvE1 and BLT1 antagonist exerted similar 
inhibitory effects on DC motility in the hapten-treated in-
flammatory skin (Fig. 4, D and E; and Videos 5–8). No addi-
tional inhibitory effect of RvE1 and BLT1 antagonist on DC 
motility under inflammatory conditions was observed (Fig. 4, 
D and E). To further clarify whether the loss of BLT1 signal-
ing on DCs intrinsically impairs DC motility, we generated 
mixed BM chimeras using BM cells from WT mice (CD45.1 
positive) and BLT1-deficient mice (CD45.2 positive). 2 mo 
after the reconstitution, mice were applied to an FITC- 
induced cutaneous DC migration assay, and the number of 
FITC+ migrated DCs in dLNs as well as the skin-resident 
DCs in steady-state were evaluated by flow cytometry. The 
migration ratio was calculated by dividing the number of 
FITC+ migrated DCs in the dLNs after FITC application 
(migrated DCs) by that of skin-resident DCs under steady 
states per square millimeter (skin-resident DCs) in WT and 
Figure 3. Inhibition of DC migration in the steady state 
by RvE1 or a BLT1 antagonist. (A) Schema of photoconver-
sion. Kaede transgenic mice were treated with vehicle, RvE1 
(200 ng/mouse), or a BLT1 antagonist (ONO-4057; 60 µg/
mouse). Then the shaved abdominal skin was irradiated with 
violet light (photoconversion) 30 min after the drug administra-
tion. 24 h after the photoconversion, the draining axillary and 
popliteal LNs were collected, stained with anti-CD11c and MHC 
class II mAbs, and subjected to flow cytometric analysis. (B) Rep-
resentative FACS plots gated on CD11c+ MHC class II+ cells in 
each condition. Numbers within the red squares indicate the 
percentage of migrated cells (Kaede-red cells) among total 
CD11c+ MHC class II+ cells. (C) Quantification of the Kaede-red–
positive CD11c+ MHC class II+ cells in dLNs (n = 3). (D) The num-
bers of each DC subset (EpCAM+ Langerhans cells, CD103+ 
dermal DCs, and CD103 dermal DCs among Kaede-red+ CD11c+ 
MHC class II+ cells in dLNs; n = 3). Results are expressed as the 
mean ± SEM. All p-values were obtained by Student’s t test:  
*, P < 0.05. All data are representative of three independent ex-










Published October 5, 2015
JEM Vol. 212, No. 11
Article
1925
with DNFB on the ears, where WT-derived memory T cells 
interact with WT or BLT1-deficient DCs. BLT1-deficient 
recipient mice, which lacked BLT1 in skin DCs, exhibited 
fewer IFN-–producing CD8+ T cells in the skin and a re-
duced ear swelling response when compared with WT recip-
ient mice (Fig. 5, E–G).
These results indicate that LTB4-BLT1 signaling facilitates 
DC motility to form DC cluster and memory T cell activation 
in the skin after hapten application. Although we could not 
completely exclude the possibility of the effect of RvE1 on 
other cells such as T cells and neutrophils, RvE1 seems to exert 
antiinflammatory roles in the elicitation phase of CHS, possi-
bly through a blockade of LTB4-BLT1 signaling on DCs.
LTB4 induces actin polymerization in DCs  
and promotes DC chemokinesis
The actin cytoskeleton is essential to the regulation of cell 
formation, and the rates of polymerization/depolymerization 
These results suggest that LTB4-BLT1 signaling facilitates 
DC cluster formation in the skin, which is abrogated by 
RvE1 treatment.
Next, we investigated whether the reduced DC cluster for-
mation in RvE1-treated WT mice and BLT1-deficient mice led 
to impaired effector T cell activation in the skin. Administration 
of RvE1 or a BLT1 antagonist during the elicitation phase sig-
nificantly suppressed the number of IFN-–producing CD8+ 
T cells in the skin, accompanied by reduced ear swelling re-
sponse (Fig. 5, C and D). The effect of RvE1 in combination 
with the BLT1 antagonist on the CD8+ T cell activation and 
the ear swelling response were similar to those induced by each 
drug treatment alone (Fig. 5, C and D).
We also sought to examine the physiological role of BLT1 
in cutaneous DCs. To address this issue, we purified LN cells 
from DNFB-sensitized WT mice, which contained DNFB-
sensitized memory T cells, and transferred into either naive 
WT or BLT1-deficient mice. Then, the mice were challenged 
Figure 4. Inhibition of DC motility in the skin by BLT1 
blockade. (A–C) Evaluation of cutaneous DC motility in the 
steady state skin. (A) Representative images of DC morphol-
ogy. CD11c-YFP mice were treated with vehicle, RvE1 (200 
ng/mouse), a BLT1 antagonist (ONO-4057; 60 µg/mouse), or 
RvE1 (200 ng/mouse) plus a BLT1 antagonist (60 µg/mouse), 
and DC morphology was examined 1 h after each drug treat-
ment. Bars, 10 µm. (B) Overlay of 100 individual DC tracks. 
Superimposed 30-min tracks of 100 randomly selected 
CD11c-YFP+ cells 1 h after each drug treatment in the x-y 
plane, setting the starting coordinates to the origin. (C) Com-
parison of CD11c-YFP+ cell displacement, track velocity, and 
straightness in B. Each symbol represents an individual cell. 
(D and E) Evaluation of cutaneous DC motility in the inflam-
matory state skin. (D) Overlay of 100 individual DC tracks 
plotted after aligning their starting positions. Ear skin of 
CD11c-YFP mice were applied with 0.5% DNFB, and the mice 
were treated with vehicle, RvE1, a BLT1 antagonist, or RvE1 
plus a BLT1 antagonist 3 h after the hapten application.  
Superimposed 30-min tracks of 100 randomly selected CD11c-
YFP+ cells 1 h after each drug treatment in the x-y plane. 
(E) Comparison of CD11c-YFP+ cell displacement, track ve-
locity, and straightness in D. (C and E) Red horizontal lines 
indicate median values. All p-values were obtained by 
Welch’s t test: *, P < 0.05. All data are representative of three 
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Next, we examined the effect of LTB4 on Rho family 
protein activation in DCs because Rho family proteins, in-
cluding Cdc42, Rac1, and Rho, play essential roles in actin 
polymerization (Lämmermann and Germain, 2014). Among 
the three Rho family proteins, LTB4 induced the conver-
sion of the GDP-bound inactivated form of Cdc42 and 
Rac1 into their GTP-bound activated form in WT BMDCs, 
which was canceled by pretreatment with RvE1 or a BLT1 
antagonist (Fig. 6, D and E). Consistently, LTB4-induced 
activation of Cdc42 and Rac1 was not observed in BLT1-
deficient BMDCs.
Finally, an in vitro transwell migration assay was per-
formed to directly examine the effect of LTB4 on DC motil-
ity. LTB4 treatment significantly enhanced BMDC migration 
toward CCL21, a chemokine for cutaneous DC migration to 
dLNs (Förster et al., 1999), and chemokine (CXC motif) li-
gand 2 (CXCL2), a chemokine for DC cluster formation in 
the skin (Natsuaki et al., 2014), when compared with vehicle 
treated-BMDCs. These effects of LTB4 were abolished by 
pretreatment with RvE1 or the BLT1 antagonist (Fig. 6 F). 
of actin are important determinants of cell motility (Edwards 
et al., 1999). Therefore, to examine how LTB4-BLT1 sig-
naling promotes DC motility, we evaluated the effect of 
LTB4 on actin filament reorganization in DCs. BMDCs 
treated with either vehicle or LTB4 were stained with Alexa 
Fluor 488–conjugated phalloidin. LTB4 induced actin pro-
trusion (lamellipodia and filopodia) and motile structures in 
DCs (Fig. 6 A), indicating that the actin filaments undergo a 
profound reorganization by LTB4 treatment. This observa-
tion was confirmed by a quantitative analysis of the cell po-
larity (long to short axis ratio) and cell roundness (Fig. 6 B). 
Consistently, the mean fluorescence intensity (MFI) of actin 
staining was significantly increased by LTB4 treatment (Fig. 
6 C). All of these changes induced by LTB4 were completely 
abolished in RvE1- or BLT1 antagonist–treated DCs and in 
BLT1-deficient DCs (Fig. 6, A–C). Moreover, no additional 
effect by RvE1 treatment on the morphology or the MFI of 
actin staining in BLT1-deficient DCs was observed (Fig. 6, 
A–C). Therefore, LTB4 induces actin filament reorganiza-
tion in DCs via BLT1, which was dampened by RvE1.
Figure 5. Attenuated DC cluster forma-
tion and effector T cell activation in the 
skin by BLT1 blockade. (A) Representative 
images of the whole-mount staining of ear 
skin stained with anti–MHC class II mAb 24 h 
after DNFB application. Mice were treated 
with vehicle, RvE1, or a BLT1 antagonist  
30 min before 0.5% DNFB application. White 
circles indicate DC cluster formation. Bars, 
100 µm. (B) Quantification of DC cluster for-
mation. Scores were assigned according to 
the size and the number of clusters (n = 4). 
(C) Number of IFN-+ CD8+ T cells per ear  
18 h after 0.3% DNFB elicitation (n = 4). Mice 
were treated with vehicle, RvE1, a BLT1 an-
tagonist, or RvE1 plus a BLT1 antagonist  
30 min before the challenge (n = 3). (D) Ear 
thickness change at 24 and 48 h after the 
challenge. Mice were treated with vehicle, 
RvE1, a BLT1 antagonist, or RvE1 plus a BLT1 
antagonist 30 min before the challenge (n = 3). 
(E) Representative FACS plots of IFN-– 
producing CD8+ T cells in the skin 18 h after  
0.5% DNFB elicitation. LN cells from DNFB-
sensitized WT mice were transferred into WT 
or BLT1-deficient mice. Recipient mice were 
challenged with 0.5% DNFB after transfer  
(n = 4). Numbers in the top right quadrants 
indicate the percentage of IFN-+ CD8+ T cells 
in total CD8+ cells. (F) Number of IFN-+ CD8+ 
T cells per ear 18 h after 0.5% DNFB elicita-
tion (n = 4). (G) Ear thickness change at 24 
and 48 h after the challenge (n = 3). Results 
are expressed as the mean ± SEM. All p-values 
were obtained by Student’s t test: *, P < 0.05. 
All data are representative of five independent 
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our results underscore the importance of LTB4-BLT1 signal-
ing on cutaneous DC motility and the subsequent immune 
response, which is abrogated by RvE1.
Previous studies suggested that the antiinflammatory ef-
fect by RvE1 is mediated by modulation of cytokine produc-
tion by DCs (Arita et al., 2005a; Haworth et al., 2008). In 
contrast, the significance of DC motility in acquired immu-
nity has been demonstrated (Honda et al., 2013; Natsuaki 
et al., 2014). Although we could not exclude the possibility 
that RvE1 modulates cytokine production by cutaneous DCs 
and affects CHS response, we propose that regulation of DC 
motility is another possible key mechanism by which RvE1 
exerts the antiinflammatory effects in acquired immunity. The 
effect of RvE1 on DC motility in cutaneous immunity is 
consistent with a previous observation in the spleen that 
RvE1 suppresses DC migration induced by the Toxoplasma 
Furthermore, RvE1 treatment exhibited no additional effects 
in BLT1-deficient DCs (Fig. 6 F). Therefore, LTB4-BLT1 
signaling seems to facilitate DC motility by promoting actin 
polymerization, which is antagonized by RvE1.
DISCUSSION
In this study, we revealed that RvE1 down-regulates DC mo-
tility in both steady state and inflammatory conditions in 
the skin and exerts its antiinflammatory effects in CHS. The 
motility of the three major skin DC subsets is similarly af-
fected by RvE1 and BLT1 deficiency both in the steady state 
and during inflammation. We propose LTB4-BLT1 signal-
ing blockade as a possible major mechanism through which 
RvE1 exerts its regulatory effects. In addition, LTB4-BLT1 
signaling facilitates cutaneous DC motility by inducing actin 
polymerization with Cdc42 and Rac1 activation. Collectively, 
Figure 6. Actin filament reorganization 
by LTB4-BLT1 signaling in DCs. (A) F-actin 
staining of DCs. WT and BLT1-deficient  
BMDCs were incubated on fibronectin-coated 
coverslips for 30 min in the presence or ab-
sence of 100 nM LTB4. The LTB4-treated cells 
were pretreated with vehicle, 100 nM RvE1, or 
10 nM BLT1 antagonist (U-75302) for 1 h.  
F-actin was stained with phalloidin (green). 
The nucleus was stained with DAPI (blue). Bars, 
5 µm. (B) Quantification of the morphological 
changes (long to short axis ratio and round-
ness) in BMDCs in A. Each symbol represents 
an individual cell. Red horizontal lines indicate 
median values. (C) The MFI of F-actin expres-
sion in BMDCs in A. Values of the MFI were 
evaluated by flow cytometry. (D) Immunoblot 
analysis for GTP- and total-Cdc42 and GTP- 
and total-Rac1 in WT and BLT1-deficinet  
BMDCs pretreated with vehicle, RvE1, or a BLT1 
antagonist and stimulated with LTB4 for  
30 min. (E) Quantification of immunoblot analy-
sis for GTP-Cdc42 and GTP-Rac1 in D (n = 3). 
The intensity of the band of Cdc42 and Rac1 
was measured by densitometry (ImageJ) 
normalized to the mean total Cdc42 and 
Rac1 intensity. (F) Transwell migration assay 
for DCs. WT or BLT1-deficient BMDCs were 
pretreated with LTB4, and the numbers of 
DCs migrated into the lower chamber con-
taining 100 nM CCL21 or 50 nM CXCL2 were 
measured 5 h later. The graphs indicate the 
percentage of migrated DCs to total input 
DCs. Results are expressed as the mean ± 
SEM. All p-values were obtained by Student’s 
t test: *, P < 0.05. All data are representative 
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Tondabayashi, Osaka, Japan). CD11c-YFP mice on B6 background were 
obtained from the Jackson Laboratory.
Reagents. APC-conjugated anti-CD11c, anti-CD44, and anti–IFN- mAbs; 
APC-Cy7–conjugated anti-B220, anti-CD4, and anti-CD11c mAbs; FITC-
conjugated anti–MHC class II mAb; PB-conjugated anti-CD11c, anti-CD45, 
and anti–MHC class II mAbs; PE-conjugated anti-CD8, anti-CD62L, and 
anti-TCR mAbs; PE-Cy7–conjugated anti-CD45 and anti–MHC class II 
mAbs; and annexin V and PI were purchased from eBioscience. BLT1 antago-
nist U-75302 was purchased from Cayman Chemical. A ChemR23 agonist 
(recombinant murine chemerin) was purchased from R&D Systems. BLT1 
antagonist ONO-4057 was provided by Ono Pharmaceutical Co., Ltd. RvE1 
was synthesized as previously described (Ogawa and Kobayashi, 2009).
DNFB-induced CHS model and adoptive transfer. Mice were sensi-
tized through the application of 25 µl of 0.5% (wt/vol) DNFB (Nacalai 
Tesque) in 4:1 acetone/olive oil (vol/vol) to their shaved abdomens. They 
were challenged on both sides of each ear with 20 µl of 0.3% (wt/vol) DNFB 
5 d after sensitization. RvE1 (200 ng/mouse in 200 µl of 1.8% ethanol in 
PBS) or its vehicle (200 µl of 1.8% ethanol in PBS) was applied 1 d before 
and on the day of sensitization or 5 d after sensitization via intravenous injec-
tion, according to a previous study (Haworth et al., 2008) with some modi-
fications. Ear thickness change was measured for each mouse before and 24 
and 48 h after the challenge using a thickness gauge (Teclok), and the differ-
ence was expressed as ear swelling. For adoptive transfer, single-cell suspen-
sions were prepared from axillary dLNs of mice 5 d after sensitization with 
0.5% DNFB. LN cells from one mouse were injected intravenously into one 
naive recipient mouse and then challenged with 0.5% DNFB.
Photoconversion. Photoconversion of the skin was performed as previously 
described (Tomura et al., 2010). In brief, Kaede transgenic mice were anes-
thetized, shaved on the abdomen, and exposed to violet light at 95 mW/cm2 
with a 436-nm bandpass filter using Spot UV curing equipment for 10 min 
(SP500; USHIO).
Immunostaining. Immunostaining for BMDCs was performed as reported 
previously (Tanizaki et al., 2010), with some modification. In brief, BMDCs 
were plated on coverslips coated with 10 µg/ml fibronectin (Sigma-Aldrich) 
for 16 h. The cells were fixed for 15 min with 3.7% formalin (Wako Pure 
Chemical Industries) and permeabilized with 0.1% Triton-X (Sigma-Aldrich) 
in PBS for 7 min at room temperature. Next, slides were incubated with 
Alexa Fluor 488–conjugated phalloidin (Invitrogen) at room temperature for 
1 h. The slides were mounted in ProLong Gold Antifade reagent (Invitrogen), 
and fluorescence images were obtained using a BIOREVO BZ-9000 system 
(Keyence). The data were further processed using ImageJ software (National 
Institutes of Health).
For whole-mount staining, the ears were split into dorsal and ventral 
halves and then incubated for 30 min at 37°C with 0.5 M ammonium thio-
cyanate. Next, the dermal sheets were separated and fixed in acetone for 
10 min at 20°C. After treatment with Image-iT FX Signal Enhancer (Invi-
trogen), the sheets were incubated with Ab to mouse MHC class II (eBiosci-
ence) followed by incubation with Ab to rat IgG conjugated to Alexa Fluor 
488 (Invitrogen). The slides were mounted with a ProLong Antifade kit and 
were observed using a fluorescence microscope (BIOREVO BZ-9000). The 
number and the size of DC clusters were evaluated in 10 fields of 1 mm2 per 
ear and were assigned scores according to the previously described criteria 
(Natsuaki et al., 2014). Histological assessment was conducted blindly by two 
different dermatopathologists.
BMDC culture. For BMDC culture, 5 × 106 BM cells generated from WT 
and BLT1-deficient mice were cultured in 10 ml cRPMI (RPMI 1640; 
Sigma-Aldrich), containing 10% heat-inactivated FCS (Invitrogen), 50 µM 
2-mercaptoethanol, 2 mM l-glutamine, 25 mM N-2-hydroxyethylpiperazine-
N-2-ethanesulfonic acid, 1 mM nonessential amino acids, 1 mM sodium py-
ruvate, 100 U/ml penicillin, and 100 µg/ml streptomycin supplemented with 
10 ng/ml of recombinant murine GM-CSF (PeproTech) for 5–7 d.
gondii–soluble tachyzoite antigens (Arita et al., 2005a). Here 
we demonstrated that the attenuated DC migration by RvE1 
was observed in WT mice but not in BLT1-deficient mice 
and that a ChemR23 agonist did not significantly influence 
DC migration. Our current findings together with the previ-
ous study suggest that RvE1 attenuates the cytokine produc-
tion by DCs and cutaneous DC migration via stimulation 
with ChemR23 and a blockade of BLT1, respectively.
In this study, we have demonstrated that LTB4-BLT1 
signaling promotes actin polymerization in DCs by induc-
ing Cdc42 and Rac1 activation, which was inhibited by RvE1. 
The aforementioned mechanism may explain the inhibitory 
mechanism of RvE1 on DC motility and morphological 
changes in the skin. In fact, BMDCs lacking Rac1 and Rac2, 
or Cdc42, exhibit round-shaped morphology and do not mi-
grate to dLNs (Benvenuti et al., 2004; Lämmermann et al., 
2009). Here we demonstrated that LTB4 was produced by 
DCs themselves, and its production was further enhanced by 
DC activation. Therefore, the aforementioned findings suggest 
that LTB4 produced by DCs themselves facilitates cutaneous 
DC motility via BLT1 to establish acquired immunity.
We recently reported that dermal DC clusters are essential 
structures that initiate effector T cell activation and that IL-1 
is a key factor in inducing the clusters (Natsuaki et al., 2014). 
In the current study, we revealed that LTB4-BLT1 signaling is 
another important mediator for DC cluster formation. It has 
been reported that IL-1 induces LTB4 production from neu-
trophils (Smith et al., 1987) and that IL-1 receptor antagonist 
down-regulates LTB4 production from monocytes (Conti 
et al., 1992, 1993). Therefore, IL-1 observed in skin inflamma-
tion (Natsuaki et al., 2014) may induce LTB4 production in 
the skin, which may lead to increased DC motility and subse-
quent DC cluster formation in the skin.
Collectively, our results newly clarified the regulatory 
mechanisms of RvE1 in vivo and the effect of LTB4-BLT1 
signaling on cutaneous DC motility. RvE1 is an endoge-
nous lipid mediator with strong antiinflammatory effects, 
and the increase of LTB4 is detected in various inflamma-
tory diseases (Honda and Kabashima, 2014); therefore, 
RvE1 may lead to the development of novel antiinflamma-
tory drugs to regulate acquired immune responses. In con-
trast, RvE1 may attenuate the resistance to microorganisms 
by inhibiting BLT1 signaling. Indeed, LTB4-BLT1 signal-
ing contributes to the exclusion of microorganisms, such as 
histoplasmosis (Secatto et al., 2014) and cytomegalovirus 
(Gaudreault and Gosselin, 2007). Therefore, cautious ex-
amination of the effect of RvE1 on infection is required for 
considering further clinical application.
MATERIALS AND METHODS
Animals. Female C57BL/6 (B6) mice were purchased from Japan SLC. All 
experiments were conducted on 8- to 12-wk-old mice. BLT1-deficient 
mice on B6 background were generated as previously described (Terawaki 
et al., 2005). Kaede transgenic mice on B6 background were generated as 
previously described (Tomura et al., 2010) and were provided by M. Tomura 
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irradiation and received mixed BM single-cell suspensions from congenic 
WT CD45.1-positive mice and BLT1-deficient CD45.2-positive mice 
with 1:1 ratio (2 × 106 cells from each strain) intravenously through the tail 
vein. The chimeric mice were used for the indicated experiment 2 mo 
after the reconstitution.
Statistical analysis. All statistical analyses were performed using Prism 4.0 
(GraphPad Software). The Student’s t test or Welch’s t test was used to calculate 
statistical differences. All p-values <0.05 were considered statistically significant.
Study approval. All experimental procedures were approved by the Insti-
tutional Animal Care and Use Committee of Kyoto University Graduate 
School of Medicine.
Online supplemental material. Videos 1–4 show DC migration in 
steady state skin in vehicle-treated (Video 1), RvE1-treated (Video 2), BLT1 
antagonist–treated (Video 3), and RvE1- plus BLT1 antagonist–treated 
(Video 4) CD11c-YFP mice. Videos 5–8 show DC migration in inflammatory 
state in vehicle-treated (Video 5), RvE1-treated (Video 6), BLT1 antagonist–
treated (Video 7), and RvE1- plus BLT1 antagonist–treated (Video 8) 
CD11c-YFP mice. Online supplemental material is available at http://www 
.jem.org/cgi/content/full/jem.20150381/DC1.
We thank H. Kitajima (Department of Work Systems and Health, Institute of 
Industrial Ecological Sciences, University of Occupational and Environmental 
Health) for advising on the statistical analyses.
This work was supported in part by Grants-in-Aid for Scientific Research from 
the Ministry of Education, Culture, Sports, Science and Technology and the Ministry 
of Health, Labour and Welfare of Japan (to K. Kabashima); Precursory Research for 
Embryonic Science and Technology, Japan Agency for Medical Research and 
Development, and Japan Agency for Medical Research and Development (to  
K. Kabashima); and the Japanese Society for Investigative Dermatology’s Fellowship 
SHISEIDO Award (to T. Honda).
The authors declare no competing financial interests.
Submitted: 3 March 2015
Accepted: 1 September 2015
REFERENCES
Ando, R., H. Hama, M. Yamamoto-Hino, H. Mizuno, and A. Miyawaki. 2002. 
An optical marker based on the UV-induced green-to-red photoconver-
sion of a fluorescent protein. Proc. Natl. Acad. Sci. USA. 99:12651–12656. 
http://dx.doi.org/10.1073/pnas.202320599
Arita, M., F. Bianchini, J. Aliberti, A. Sher, N. Chiang, S. Hong, R. Yang, N.A. 
Petasis, and C.N. Serhan. 2005a. Stereochemical assignment, antiinflamma-
tory properties, and receptor for the omega-3 lipid mediator resolvin E1. 
J. Exp. Med. 201:713–722. http://dx.doi.org/10.1084/jem.20042031
Arita, M., M. Yoshida, S. Hong, E. Tjonahen, J.N. Glickman, N.A. Petasis, R.S. 
Blumberg, and C.N. Serhan. 2005b. Resolvin E1, an endogenous lipid 
mediator derived from omega-3 eicosapentaenoic acid, protects against 
2,4,6-trinitrobenzene sulfonic acid-induced colitis. Proc. Natl. Acad. Sci. 
USA. 102:7671–7676. http://dx.doi.org/10.1073/pnas.0409271102
Arita, M., T. Ohira, Y.P. Sun, S. Elangovan, N. Chiang, and C.N. Serhan. 
2007. Resolvin E1 selectively interacts with leukotriene B4 receptor 
BLT1 and ChemR23 to regulate inflammation. J. Immunol. 178:3912–
3917. http://dx.doi.org/10.4049/jimmunol.178.6.3912
Benvenuti, F., S. Hugues, M. Walmsley, S. Ruf, L. Fetler, M. Popoff, 
V.L. Tybulewicz, and S. Amigorena. 2004. Requirement of Rac1 and 
Rac2 expression by mature dendritic cells for T cell priming. Science. 
305:1150–1153. http://dx.doi.org/10.1126/science.1099159
Conti, P., M.R. Panara, R.C. Barbacane, F.C. Placido, M. Bongrazio, M. Reale, 
R.A. Dempsey, and S. Fiore. 1992. Blocking the interleukin-1 recep-
tor inhibits leukotriene B4 and prostaglandin E2 generation in human 
monocyte cultures. Cell. Immunol. 145:199–209. http://dx.doi.org/ 
10.1016/0008-8749(92)90323-H
Conti, P., M.R. Panara, R.C. Barbacane, M. Bongrazio, R.A. Dempsey, and 
M. Reale. 1993. Human recombinant IL-1 receptor antagonist (IL-1Ra) 
Flow cytometry. Single-cell suspensions from skin dLNs were prepared 
5 d after sensitization and stained with the indicated Abs. For the preparation 
of single-cell suspensions from skin, the ears were split into dorsal and ventral 
halves, and the cartilage was removed. The ear skin was incubated for 1 h in 
cRPMI containing 2 mg/ml collagenase II (Worthington Biochemical Cor-
poration) and 100 µg/ml DNase I (Sigma-Aldrich). The cell suspensions 
were filtered using a 40-µm cell strainer and stained with the indicated Abs. 
These cells were subjected to a flow cytometry (Fortessa; BD), and the data 
were analyzed with FlowJo software (Tree Star).
FITC-induced cutaneous DC migration. The shaved abdomens of the 
mice were painted with 200 µl of 1% (wt/vol) FITC (Sigma-Aldrich) dissolved 
in a 1:1 (vol/vol) acetone/dibutyl phthalate mixture. RvE1 (200 ng/mouse in 
200 µl of 1.8% ethanol in PBS) or its vehicle (200 µl of 1.8% ethanol in PBS) was 
applied intravenously 30 min before and 1 d after FITC application. Samples of 
axillary LNs were taken for flow cytometric analysis 48 h after FITC application. 
The cutaneous DCs migrating into the axillary dLNs were then analyzed by 
flow cytometry using Flow-Count Fluorospheres (Beckman Coulter).
Transmigration assay. Single-cell suspensions from BMDCs were incubated 
for 30 min with TNF (R&D Systems) or LTB4 (Cayman Chemical) and tested 
for transmigration across uncoated 5-µm transwell filters (Corning) to 100 nM 
CCL21 (R&D Systems), 50 nM CXCL2 (R&D Systems), or medium for 5 h. 
Migrating cells were subjected to flow cytometry. RPMI 1640 with 0.5% fatty 
acid–free BSA (EMD Millipore) was used as the culture medium.
Two-photon microscopy. Two-photon imaging was performed as previ-
ously described (Natsuaki et al., 2014), with some modifications. In brief, 
mice were anesthetized with isoflurane and were positioned on the heating 
plate on the stage of a two-photon microscope (IX-81; Olympus), with their 
earlobes fixed beneath coverslips with a single drop of immersion oil. Stacks 
of three images, spaced 4 µm apart, were acquired every 1 min for the indi-
cated period. Videos were further processed using Imaris software (Bitplane). 
To visualize cutaneous DCs, CD11c-YFP transgenic mice, in which CD11c-
positive cells express cytoplasmic YFP, were used (Lindquist et al., 2004). 
For the evaluation of cutaneous DC motility, we randomly selected 100 DCs 
in the observation field and tracked the DC movement in the same time 
spans (30 min) using Imaris software.
Western blotting. Cdc42 and Rac1 activity assays were performed accord-
ing to the manufacturer’s protocol. In brief, BMDCs were lysed directly in 
their 10-cm plates with ice-cold lysis buffer. Lysates were then incubated at 
4°C with 10 µg PAK-PBD beads (Cytoskeleton, Inc.). Proteins from the 
total cell lysate, as well as the bead pellets, were separated by 10% SDS-
PAGE gel, transferred to a nitrocellulose membrane, and blotted for the ap-
propriate GTPase using a mouse monoclonal anti-Cdc42 Ab (Cytoskeleton, 
Inc.) or a mouse monoclonal anti-Rac1 Ab (Cytoskeleton, Inc.).
Lymphocyte proliferation assay. Single-cell suspensions were prepared 
from axillary dLNs of mice 5 d after sensitization with DNFB. One million 
LN cells were cultured with or without the different concentrations of dini-
trobenzene sulfonic acid (DNBS; 50 and 100 µg/ml; Alfa Aesar) for 72 h, 
pulsed with 0.5 µCi [3H]thymidine for the last 24 h, and subjected to liquid 
scintillation counting. For the measurement of cytokine production, culture 
supernatants were collected 48 h after incubation. The amount of IFN- was 
measured by ELISA (BD) according to the manufacturer’s instructions.
ELISA. BMDCs (106/well) were stimulated with or without 100 ng/ml 
TNF for 12 h. For measurement of LTB4 production, culture supernatants 
were collected 12 h after incubation. The LTB4 concentration of culture 
supernatants was measured by ELISA (Cayman Chemical) according to the 
manufacturer’s instructions.
Generation of BM chimera mice. To generate mixed BM chimera 










Published October 5, 2015
1930 RvE1 regulates DC migration in the skin | Sawada et al.
inhibits leukotriene B4 generation from human monocyte suspensions 
stimulated by lipopolysaccharide (LPS). Clin. Exp. Immunol. 91:526–
531. http://dx.doi.org/10.1111/j.1365-2249.1993.tb05936.x
Dyerberg, J., H.O. Bang, E. Stoffersen, S. Moncada, and J.R. Vane. 1978. 
Eicosapentaenoic acid and prevention of thrombosis and atherosclerosis? 
Lancet. 312:117–119. http://dx.doi.org/10.1016/S0140-6736(78)91505-2
Edwards, D.C., L.C. Sanders, G.M. Bokoch, and G.N. Gill. 1999. 
Activation of LIM-kinase by Pak1 couples Rac/Cdc42 GTPase signal-
ling to actin cytoskeletal dynamics. Nat. Cell Biol. 1:253–259. http://
dx.doi.org/10.1038/12963
Förster, R., A. Schubel, D. Breitfeld, E. Kremmer, I. Renner-Müller, E. Wolf, 
and M. Lipp. 1999. CCR7 coordinates the primary immune response by 
establishing functional microenvironments in secondary lymphoid organs. 
Cell. 99:23–33. http://dx.doi.org/10.1016/S0092-8674(00)80059-8
Gaudreault, E., and J. Gosselin. 2007. Leukotriene B4-mediated release of 
antimicrobial peptides against cytomegalovirus is BLT1 dependent. Viral 
Immunol. 20:407–420. http://dx.doi.org/10.1089/vim.2006.0099
Haas-Stapleton, E.J., Y. Lu, S. Hong, M. Arita, S. Favoreto, S. Nigam, C.N. 
Serhan, and N. Agabian. 2007. Candida albicans modulates host defense 
by biosynthesizing the pro-resolving mediator resolvin E1. PLoS ONE. 
2:e1316. http://dx.doi.org/10.1371/journal.pone.0001316
Haworth, O., M. Cernadas, R. Yang, C.N. Serhan, and B.D. Levy. 2008. 
Resolvin E1 regulates interleukin 23, interferon- and lipoxin A4 to 
promote the resolution of allergic airway inflammation. Nat. Immunol. 
9:873–879. http://dx.doi.org/10.1038/ni.1627
Honda, T., and K. Kabashima. 2014. Leukotrienes as key mediators and am-
plifiers in allergic inflammation: insights from the bench and clinic. Exp. 
Dermatol. 23:95–96. http://dx.doi.org/10.1111/exd.12282
Honda, T., S. Nakajima, G. Egawa, K. Ogasawara, B. Malissen, Y. Miyachi, 
and K. Kabashima. 2010. Compensatory role of Langerhans cells and 
langerin-positive dermal dendritic cells in the sensitization phase of mu-
rine contact hypersensitivity. J. Allergy Clin. Immunol. 125:1154–1156. 
http://dx.doi.org/10.1016/j.jaci.2009.12.005
Honda, T., G. Egawa, S. Grabbe, and K. Kabashima. 2013. Update of im-
mune events in the murine contact hypersensitivity model: toward the 
understanding of allergic contact dermatitis. J. Invest. Dermatol. 133:303–
315. http://dx.doi.org/10.1038/jid.2012.284
Honda, T., J.G. Egen, T. Lämmermann, W. Kastenmüller, P. Torabi-Parizi, 
and R.N. Germain. 2014. Tuning of antigen sensitivity by T cell re-
ceptor-dependent negative feedback controls T cell effector function 
in inflamed tissues. Immunity. 40:235–247. http://dx.doi.org/10.1016/ 
j.immuni.2013.11.017
Horrobin, D.F. 1987. Low prevalences of coronary heart disease (CHD), pso-
riasis, asthma and rheumatoid arthritis in Eskimos: are they caused by 
high dietary intake of eicosapentaenoic acid (EPA), a genetic variation of 
essential fatty acid (EFA) metabolism or a combination of both? Med. 
Hypotheses. 22:421–428. http://dx.doi.org/10.1016/0306-9877(87)90037-5
Lämmermann, T., and R.N. Germain. 2014. The multiple faces of leu-
kocyte interstitial migration. Semin. Immunopathol. 36:227–251. http://
dx.doi.org/10.1007/s00281-014-0418-8
Lämmermann, T., J. Renkawitz, X. Wu, K. Hirsch, C. Brakebusch, and 
M. Sixt. 2009. Cdc42-dependent leading edge coordination is essential 
for interstitial dendritic cell migration. Blood. 113:5703–5710. http://
dx.doi.org/10.1182/blood-2008-11-191882
Lin, Y., X. Yang, W. Yue, X. Xu, B. Li, L. Zou, and R. He. 2014. Chemerin 
aggravates DSS-induced colitis by suppressing M2 macrophage 
polarization. Cell. Mol. Immunol. 11:355–366. http://dx.doi.org/10 
.1038/cmi.2014.15
Lindquist, R.L., G. Shakhar, D. Dudziak, H. Wardemann, T. Eisenreich, M.L. 
Dustin, and M.C. Nussenzweig. 2004. Visualizing dendritic cell networks 
in vivo. Nat. Immunol. 5:1243–1250. http://dx.doi.org/10.1038/ni1139
Luangsay, S., V. Wittamer, B. Bondue, O. De Henau, L. Rouger, M. 
Brait, J.D. Franssen, P. de Nadai, F. Huaux, and M. Parmentier. 2009. 
Mouse ChemR23 is expressed in dendritic cell subsets and macro-
phages, and mediates an anti-inflammatory activity of chemerin in a 
lung disease model. J. Immunol. 183:6489–6499. http://dx.doi.org/10 
.4049/jimmunol.0901037
Mori, T., K. Kabashima, R. Yoshiki, K. Sugita, N. Shiraishi, A. Onoue, E. 
Kuroda, M. Kobayashi, U. Yamashita, and Y. Tokura. 2008. Cutaneous 
hypersensitivities to hapten are controlled by IFN--upregulated kera-
tinocyte Th1 chemokines and IFN--downregulated langerhans cell Th2 
chemokines. J. Invest. Dermatol. 128:1719–1727. http://dx.doi.org/ 
10.1038/jid.2008.5
Natsuaki, Y., G. Egawa, S. Nakamizo, S. Ono, S. Hanakawa, T. Okada, N. 
Kusuba, A. Otsuka, A. Kitoh, T. Honda, et al. 2014. Perivascular leuko-
cyte clusters are essential for efficient activation of effector T cells in the 
skin. Nat. Immunol. 15:1064–1069. http://dx.doi.org/10.1038/ni.2992
Ogawa, N., and Y. Kobayashi. 2009. Total synthesis of resolving E1. Tetrahedron 
Lett. 50:6079–6082. http://dx.doi.org/10.1016/j.tetlet.2009.08.061
Secatto, A., E.M. Soares, G.A. Locachevic, P.A. Assis, F.W. Paula-Silva, 
C.H. Serezani, A.I. de Medeiros, and L.H. Faccioli. 2014. The leukotri-
ene B₄/BLT₁ axis is a key determinant in susceptibility and resistance to 
histoplasmosis. PLoS ONE. 9:e85083. http://dx.doi.org/10.1371/journal 
.pone.0085083
Serhan, C.N., N. Chiang, and T.E. Van Dyke. 2008. Resolving inflamma-
tion: dual anti-inflammatory and pro-resolution lipid mediators. Nat. 
Rev. Immunol. 8:349–361. http://dx.doi.org/10.1038/nri2294
Smith, R.J., D.E. Epps, J.M. Justen, L.M. Sam, M.A. Wynalda, F.A. 
Fitzpatrick, and F.S. Yein. 1987. Human neutrophil activation with 
interleukin-1. A role for intracellular calcium and arachidonic acid li-
poxygenation. Biochem. Pharmacol. 36:3851–3858. http://dx.doi.org/ 
10.1016/0006-2952(87)90449-7
Tanizaki, H., G. Egawa, K. Inaba, T. Honda, S. Nakajima, C.S. Moniaga, A. 
Otsuka, T. Ishizaki, M. Tomura, T. Watanabe, et al. 2010. Rho-mDia1 
pathway is required for adhesion, migration, and T-cell stimulation in 
dendritic cells. Blood. 116:5875–5884. http://dx.doi.org/10.1182/blood- 
2010-01-264150
Terawaki, K., T. Yokomizo, T. Nagase, A. Toda, M. Taniguchi, K. 
Hashizume, T. Yagi, and T. Shimizu. 2005. Absence of leukotriene B4 
receptor 1 confers resistance to airway hyperresponsiveness and Th2-type 
immune responses. J. Immunol. 175:4217–4225. http://dx.doi.org/10 
.4049/jimmunol.175.7.4217
Tomura, M., T. Honda, H. Tanizaki, A. Otsuka, G. Egawa, Y. Tokura, H. 
Waldmann, S. Hori, J.G. Cyster, T. Watanabe, et al. 2010. Activated 
regulatory T cells are the major T cell type emigrating from the skin 
during a cutaneous immune response in mice. J. Clin. Invest. 120:883–
893. http://dx.doi.org/10.1172/JCI40926
Tull, S.P., C.M. Yates, B.H. Maskrey, V.B. O’Donnell, J. Madden, R.F. Grimble, 
P.C. Calder, G.B. Nash, and G.E. Rainger. 2009. Omega-3 Fatty acids 
and inflammation: novel interactions reveal a new step in neutrophil 











Published October 5, 2015
